Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
BOULDER, CO—Joseph P. Lyssikatos, the Chief Scientific Officer at Enliven Therapeutics, Inc. (NASDAQ:ELVN), executed stock sales amounting to $80,365, according to a recent SEC filing. The transactions, dated April 21, 2025, involved the sale of 5,000 shares of Enliven Therapeutics’ common stock at prices ranging from $16.0274 to $16.7208 per share. The stock has shown strong momentum recently, gaining nearly 12% in the past week, according to InvestingPro data.
These sales were conducted under a pre-established Rule 10b5-1 trading plan, which Lyssikatos adopted on November 15, 2024. Following these transactions, Lyssikatos holds 997,688 shares indirectly, through The Lyssikatos Revocable Trust, where he serves as trustee.
The sales were executed in multiple trades, with the weighted average sale prices reflecting the range in which the shares were sold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.